Clinical Trial Update: Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women [Phase 1]

View source ↗

Summary

Phase 1 single ascending-dose study of CEP-37251 in healthy postmenopausal women to evaluate safety, pharmacokinetics, and pharmacodynamics; the trial status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Loss
• Osteoporosis

Drugs mentioned

• CEP-37251

Snippet

Sponsor: Cephalon | Conditions: Bone Loss, Osteoporosis | Phase 1 | Status: TERMINATED